CelLBxHealth and AstraZeneca sign Master Services Agreement

Published: 2-Jun-2026
Pharmaceutical

The new contract establishes CelLBxHealth as a qualified service provider to AstraZeneca, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples with its Parsortix platform

The circulating tumour cell (CTC) intelligence firm CelLBxHealth has announced that it has entered into a Master Services Agreement with AstraZeneca.

The new agreement will appoint CelLBxHealth as a qualified service provider to AstraZeneca, enabling the company to support drug discovery and development through CTC-powered analytics of clinical trial samples using its Parsortix platform.

Peter Collins, CEO of CelLBxHealth, commented: "We are delighted to enter into this Master Services Agreement, which enables AstraZeneca to access our capabilities across their development pipeline."

We look forward to delivering strong and productive outcomes through this framework.

  • Companies:
  • AstraZeneca
See more

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Read more
Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation

Trending Articles

  1. Nestlé Health Science and IdB partner to bring VOWST to Europe Nestlé Health Science and IdB Holding have signed a licensing agreement to seek EMA approval for VOWST, the only FDA-approved oral live biotherapeutic for recurrent C. diff prevention
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Pharma supply chains face record drug shortages as geopolitical, cyber and quality risks converge A new Moody's report identifies four compounding risk factors driving pharmaceutical supply chain instability and warns that siloed risk management is leaving the sector dangerously exposed
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    No more needles? How intradermal delivery could transform vaccine access A new review has put forward novel needle-free Intradermal (ID) delivery formats as an effective alternative to traditional administration using needles, with the technologies demonstrating improved immunisation coverage and cost savings
  4. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
  5. Samsung Bioepis launches aflibercept biosimilar OPUVIZ across Europe The Eylea-referencing biosimilar becomes Samsung Bioepis's fifth directly commercialised product in Europe, expanding ophthalmology treatment access for patients with retinal conditions

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Research & Development

AstraZeneca puts $2.5bn into Chinese R&D and manufacturing capabilities

The pharmaceutical giant will establish its sixth strategic R&D centre in China, as well as novel research and manufacturing agreements in the region
Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC
Regulatory

AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC

Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Regulatory

AstraZeneca’s Tagrisso plus chemo for EGFR-mutated lung cancer approved in Japan

The approval comes off the back of the positive Phase III FLAURA2 trial results, showing a significant improvement in PFS compared with Tagrisso monotherapy
Pharmaceutical

Lessons learned: AstraZeneca’s supply chain resilience during the pandemic

With 26 manufacturing facilities and a global network of more than 250 suppliers, AstraZeneca’s Global Operations Manufacturing footprint is not only large in scale, it's also highly complex and positioned to deliver medicines to patients worldwide
Subscribe now